INTESTINAL FATE OF 5-AMINOSALICYLIC ACID: REGIONAL AND SYSTEMIC KINETIC STUDIES IN RELATION TO INFLAMMATORY BOWEL DISEASE-Reference-Cited by-同舟云学术

INTESTINAL FATE OF 5-AMINOSALICYLIC ACID: REGIONAL AND SYSTEMIC KINETIC STUDIES IN RELATION TO INFLAMMATORY BOWEL DISEASE

Published:1997-10 Issue: Volume:81 Page:1-30
ISSN:0901-9928
Container-title:Pharmacology & Toxicology
language:en
Short-container-title:

Author:

Bondesen Stig

Publisher

Wiley

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0773.1997.tb01944.x/fullpdf

Reference134 articles.

1. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid;Ahnfelt-Rønne;Gastroenterology,1990

2. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease;Allgayer;Gastroenterology,1989

3. Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcer-ative colitis;Allgayer;Eur. J. Clin. Pharmacol.,1984

4. Determination of the pK values of 5-aminosalicylic acid and N-acetylaminosalicylic acid and comparison of the pH dependent lipid-water partition coefficients of sulphasalazine and its metabolites;Allgayer;Arzneimittelforschung,1985

5. Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission;Almer;Scand. J. Gastroenterology,1991

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of postprandial gastric conditions on in vitro drug release from modified release mesalamine formulations;Journal of Drug Delivery Science and Technology;2024-09

2. Practice Examples of Academic Detailing —Prescription Support Based on Basic Pharmaceutical Science and Evidence;YAKUGAKU ZASSHI;2019-08-01

3. Potential of low molecular weight natural polysaccharides for colon targeted formulation and its evaluation in human by Gamma Scintigraphy;Journal of Pharmaceutical Investigation;2019-07-09

4. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis;Clinical Pharmacokinetics;2018-05-12

5. The safety of non-biological treatments in Ulcerative Colitis;Expert Opinion on Drug Safety;2017-06-19